Literature DB >> 32425374

Clinicopathological Profile of Castleman's Disease in Indian Population: Experience From a Tertiary Care Center.

Ashok Singh1, Suvendu Purkait2, Saumyaranjan Mallick3, Prashant Ramteke3, Chandan Krushna Das4, Ajay Gogia5, Maher Chand Sharma3, Lalit Kumar5.   

Abstract

Castleman's disease (CD), also known as angiofollicular lymph node hyperplasia, a rare, non-malignant chronic lymphoproliferative disease characterized by, uni or multicentric lymphadenopathy. There is limited information about the clinicopathological variations and associations of this entity. A total of 50 cases of CD were retrieved from the archives, between the years 2005-2017. The cases were divided into pediatric (0-18 years), young adult (age ≤ 40 years) and older adult groups (age > 40 years respectively). Detailed clinicopathological correlation was done. The age range was 6-74 years. There was a male predominance (M: F-1.6:1). The majority (72%; 36/50) of the patients were adults; 46% young adult and 28% older adult, while only 28% (14/50) were of pediatric. Majority (78%) showed features of unicentric Castleman disease (UCD) while rest 22% presented with multi centric Castleman disease (MCD). Systemic symptoms were more frequent in MCD as compared to UCD cases (p = 0.06). The majority of the cases (40/50; 80%) were of the hyaline vascular type. Two of the cases showed mixed histological feature. Out of 50 patients 29 patient's treatment details are available. Majority unicentric cases were cases surgically excised 14/17 (82.3%). Three patients 3/17 (17.6%) were treated with chemotherapy. In multicentric Castleman's disease group, six of the 12 cases with MCD were managed by chemotherapy. One patient died of progressive disease. Castleman disease has varied clinical presentation and is often associated with other diseases. A high degree of suspicion and careful histological examination is required in order not to miss this entity. © Indian Society of Hematology and Blood Transfusion 2019.

Entities:  

Keywords:  Castleman disease; India; Multicentric

Year:  2019        PMID: 32425374      PMCID: PMC7229093          DOI: 10.1007/s12288-019-01191-w

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  25 in total

1.  Localized mediastinal lymphnode hyperplasia resembling thymoma.

Authors:  B CASTLEMAN; L IVERSON; V P MENENDEZ
Journal:  Cancer       Date:  1956 Jul-Aug       Impact factor: 6.860

2.  Clinical features and treatment of multicentric castleman's disease : a retrospective study of 21 Japanese patients at a single institute.

Authors:  Hiroshi Kawabata; Norimitsu Kadowaki; Momoko Nishikori; Toshio Kitawaki; Tadakazu Kondo; Takayuki Ishikawa; Hajime Yoshifuji; Noriyuki Yamakawa; Yoshitaka Imura; Tsuneyo Mimori; Yumi Matsumura; Yoshiki Miyachi; Takeshi Matsubara; Motoko Yanagita; Hironori Haga; Akifumi Takaori-Kondo
Journal:  J Clin Exp Hematop       Date:  2013

Review 3.  Diagnosis and management of Castleman disease.

Authors:  Jacob D Soumerai; Aliyah R Sohani; Jeremy S Abramson
Journal:  Cancer Control       Date:  2014-10       Impact factor: 3.302

4.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Authors:  G Frizzera; B A Peterson; E D Bayrd; A Goldman
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

5.  Castleman's disease in children: the experience of a children's hospital in Africa.

Authors:  K L Taylor; R O Kaschula
Journal:  Pediatr Pathol Lab Med       Date:  1995 Nov-Dec

6.  A retrospective study of unicentric and multicentric Castleman's disease: a report of 52 patients.

Authors:  Bo Ye; Shu-Geng Gao; Wang Li; Long-Hai Yang; Shou-Hua Zhao; Ke Ma; Xiao-Lei Zhu; Xiang-Yang Liu; Ke-Ling Sun
Journal:  Med Oncol       Date:  2009-11-24       Impact factor: 3.064

7.  Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy.

Authors:  Hee Yeon Seo; Eui Bae Kim; Jee Won Kim; Bong Kyoung Shin; Seok Jin Kim; Byung Soo Kim
Journal:  Cancer Res Treat       Date:  2009-06-30       Impact factor: 4.679

8.  Castleman's disease and HIV infection in Australia.

Authors:  S Loi; D Goldstein; K Clezy; S T Milliken; J Hoy; M Chipman
Journal:  HIV Med       Date:  2004-05       Impact factor: 3.180

9.  Clinical and experimental study of Castleman disease in children.

Authors:  Jun Zhang; ChangChun Li; LinYa Lv; Chao Yang; Xiang Ru Kong; Jin Zhu; Yun Zhang; Shan Wang
Journal:  Pediatr Blood Cancer       Date:  2014-09-11       Impact factor: 3.167

10.  Clinical spectrum of intrathoracic Castleman disease: a retrospective analysis of 48 cases in a single Chinese hospital.

Authors:  Jin Mei Luo; Shan Li; Hui Huang; Jian Cao; Kai Xu; Ya Lan Bi; Rui E Feng; Cheng Huang; Ying Zhi Qin; Zuo Jun Xu; Yi Xiao
Journal:  BMC Pulm Med       Date:  2015-04-09       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.